Skip to the content
Altai Oncology - Softwarelogo darklogo light
  • Library
  • Articles
  • Patient Education
  • F.A.Q.
  • Contact Us
Altai Oncology - Softwarelogo darklogo light
New Protocol: Mosunetuzumab subQ with Polatuzumab Vedotin for Rel/Reg Large B-Cell Lymphoma
Altai Protocol Library

New Protocol: Mosunetuzumab subQ with Polatuzumab Vedotin for Rel/Reg Large B-Cell Lymphoma

U. Darda Bayraktar, MD
2025-12-08
New Protocol: Fuzuloparib with Apatinib for BRCA1/2 Mutated Breast Cancer
Altai Protocol Library

New Protocol: Fuzuloparib with Apatinib for BRCA1/2 Mutated Breast Cancer

U. Darda Bayraktar, MD
2025-12-08
New Reference: Adjuvant Capecitabine for Triple-Negative Breast Cancer
Altai Protocol Library

New Reference: Adjuvant Capecitabine for Triple-Negative Breast Cancer

U. Darda Bayraktar, MD
2025-12-08
New Reference: Amivantamab - Lazertinib for NSCLC with Atypical EGFR Mutations
Altai Protocol Library

New Reference: Amivantamab – Lazertinib for NSCLC with Atypical EGFR Mutations

U. Darda Bayraktar, MD
2025-12-08
New Drug: Sevabertinib in Advanced HER2-Mutant NSCLC
Altai Protocol Library

New Drug: Sevabertinib in Advanced HER2-Mutant NSCLC

U. Darda Bayraktar, MD
2025-11-17
New Drug: Sacituzumab Tirumotecan for EGFR-Mutated Advanced NSCLC
Altai Protocol Library

New Drug: Sacituzumab Tirumotecan for EGFR-Mutated Advanced NSCLC

U. Darda Bayraktar, MD
2025-11-17
New Reference: Rucaparib for Maintenance in Advanced Ovarian Cancer
Altai Protocol Library

New Reference: Rucaparib for Maintenance in Advanced Ovarian Cancer

U. Darda Bayraktar, MD
2025-11-17
New Indication: Trastuzumab Deruxtecan with Pertuzumab for First-Line Metastatic Her2-Positive Breast Cancer
Altai Protocol Library

New Indication: Trastuzumab Deruxtecan with Pertuzumab for First-Line Metastatic Her2-Positive Breast Cancer

U. Darda Bayraktar, MD
2025-11-17
New Indication: Neoadjuvant Trastuzumab Deruxtecan For High-Risk her2-Positive Breast Cancer
Altai Protocol Library

New Indication: Neoadjuvant Trastuzumab Deruxtecan For High-Risk her2-Positive Breast Cancer

U. Darda Bayraktar, MD
2025-11-17
New Reference: 3 vs 6 Cycles of Chemotherapy for Advanced Urothelial Carcinoma
Altai Protocol Library

New Reference: 3 vs 6 Cycles of Chemotherapy for Advanced Urothelial Carcinoma

U. Darda Bayraktar, MD
2025-11-17

Posts pagination

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31
  • Library
  • F.A.Q.
  • Contact Us

Privacy Policy

Altai, Inc (USA)

30 N Gould St, Ste 6801

Sheridan, WY, 82801, USA

Phone: +1 (978) 393 0042

Altay Tıp Sağlık Yazılım AŞ (Türkiye)

Mutlukent Mah Manuk Bey Sk No: 4

Çankaya, Ankara, 06800, Türkiye

Phone: +90 (312) 911 5735

Our Terms & Privacy Policy

Copyright - 2024 - Altai Inc - All rights reserved

Back to top Drag
  • Library
  • Articles
  • Patient Education
  • F.A.Q.
  • Contact Us

jghghjghjghhgj